


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



PATENT
Attorney Docket No.: 015280-386200US
Client Reference No.: E-070-1999/2-US-03

On 14 Oct. 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Malinda Adajit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCALA et al.

Application No.: 09/869,003

Filed: September 25, 2001

For: NOVEL HIV RELATED PEPTIDES

Examiner: Jeffrey J. Stucker

Art Unit: 1648

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Carol A. Fang
Reg. No. 48,631

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
CAF/llc
60328972 v1



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **2****Complete if Known**

Application Number	09/869,003
Filing Date	September 25, 2001
First Named Inventor	SCALA
Art Unit	1648
Examiner Name	Jeffrey J. Stucker
Attorney Docket Number	015280-386200US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A8	BONNYCASTLE, et al.; "The Identification of "HIV-1-mimic" Petides Using Antibodies from the Sera of HIV-1 Infected, Long-Term Non-Progressors;" <u>Conf Adv AIDS Vaccine Dev</u> ; May 4-7, 1997; pp. 109; United States.	
	A9	BOOTS, et al.; "Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries;" <u>AIDS Research and Human Retroviruses</u> ; 1997; Volume 13; Number 18; Mary Ann Liebert, Inc.	
	A10	BUCHBINDER, et al.; "HIV-Infected Long-Term Nonprogressors: Epidemiology, Mechanisms of Delayed Progression, and Clinical and Research Implications;" <u>Microbes and Infection</u> ; November 1999; pp. 1113-1120; Volume 1.	
	A11	COTROPIA, et al.; "A Human Monoclonal Antibody to HIV-1 gp41 With Neutralizing Activity Against Diverse Laboratory Isolates;" <u>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</u> ; 1996; pp. 221- 232; Volume 12; Lippincott-Raven Publishers; Philadelphia.	
	A12	D'SOUZA, et al.; "Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials;" <u>The Journal of Infectious Diseases</u> ; 1997; pp. 1056-1062; Volume 175.	
	A13	FELICI, et al.; "Selection of Antibody Ligands from a Large Library of Oligopeptides Expressed on a Multivalent Exposition Vector;" <u>Journal of Molecular Biology</u> ; 1991; pp. 301-310; Number 2; Academic Press Limited; London, Great Britain.	
	A14	HAESEVELDE, et al.; "Genomic Cloning and Complete Sequence Analysis of a Highly Divergent African Human Immunodeficiency Virus Isolate;" <u>Journal of Virology</u> ; March 1994; pp. 1586-1596; Volume 68; Number 3; American Society for Microbiology.	
	A15	HOGERVORST, et al.; "Predictors for Non- and Slow Progression in Human Immunodeficiency Virus (HIV) Type 1 Infection: Low Viral RNA Copy Numbers in Serum and Maintenance of High HIV-1 p24-Specific but Not V3-Specific Antibody Levels;" <u>The Journal of Infectious Diseases</u> ; 1995; pp. 811-821; Volume 171; The University of Chicago.	
	A16	IDA, et al.; "HIV Type 1 V3 Variation Dynamics in Vivo: Long-Term Persistence of Non-Syncytium-Inducing Genotypes during the Course of Progressive AIDS;" <u>AIDS Research and Human Retroviruses</u> ; 1997; pp. 1597-1609; Volume 13; Number 18; Mary Ann Liebert, Inc.	
	A17	MONTEFIORI, et al.; Neutralizing and Infection-Enhancing Antibody Responses to Human Immunodeficiency Virus Type 1 in Long-Term Nonprogressors;" <u>The Journal of Infectious Diseases</u> ; 1996; pp. 60-67; Volume 173; The University of Chicago.	
	A18	PANTALEO, et al.; "Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection;" <u>Long-Term Nonprogressive HIV Infection</u> ; January 26, 1995; pp. 209-216; Volume 332; Number 4; The New England Journal of Medicine.	
	A19	RUSCONI, et al.; "Patterns of in Vitro Anti-Human Immunodeficiency Virus Type 1 Antibody Production in Long-Term Nonprogressors;" <u>Clinical Immunology and Immunopathology</u> ; December 1997; pp. 320-323; Volume 85; Number 3; Academic Press.	
	A20	TORÁN, et al. "Molecular Analysis of HIV-1 gp120 Antibody Response using Isotype IgM and IgG phage display libraries from a Long-Term Non-Progressor HIV-1-Infected Individual;" <u>Eur. J. Immunol</u> ; 1999; pp. 2666-2675; Volume 29; WILEY-VCH Verlag GmbH; Weinheim.	
	A21	VERONESE, et al.; "Structural Mimicry and Enhanced Immunogenicity of Peptide Epitopes Displayed on Filamentous Bacteriophage The V3 Loop of HIV-1 gp120;" <u>J. Mol Biol</u> ; 1994; pp. 167-172; Volume 243; Academic Press Limited.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.